Bone turnover markers (BTMs) are useful parameters for assessing fracture risk and unlike bone mineral density (BMD), can be measured at any institution. However, BTM values have not been established in patients post-allogeneic hematopoietic stem cell transplantation (allo-HSCT). We investigated the practicality of BTMs in patients who underwent allo-HSCT by measuring levels of the serum bone resorption marker, tartrate-resistant acid phosphatase-5b (TRACP-5b), and the bone formation marker, bone-specific alkaline phosphatase (BAP), together with BMD, 1 month before and 6 months after allo-HSCT. Patients were classified into either the alendronate group (n = 14) if alendronate treatment (35 mg orally per week) was administered before allo-HSCT or within 1 month after allo-HSCT, or the control group (n = 16), in which patients did not receive alendronate treatment. Despite the high frequency of corticosteroids users in the alendronate group (71.4 vs. 18.9%; p < 0.01), the mean percentage changes in BMD at the lumbar spine (− 2.9 vs. − 3.1%; p = 0.44) and femoral neck (− 3.2 vs. − 4.1%; p = 1.00), TRACP-5b levels (− 4.8 vs. 9.9%; p = 0.45), and BAP levels (6.9 vs. 1.0%; p = 0.85) during 6 months did not differ significantly between the alendronate and control groups. Additionally, the percentage changes in BMD at the lumbar spine were negatively associated with the TRACP-5b levels 6 months after allo-HSCT (p = 0.03, r = 0.40). Our results indicate the possible effectiveness of alendronate treatment in allo-HSCT patients. BTM levels could be useful to monitor the BMD changes.

骨转换标记（BTM）是评估骨折风险的有用参数，与骨矿物质密度（BMD）不同，可以在任何机构进行测量。然而，尚未在异基因造血干细胞移植（allo-HSCT）患者中确定BTM值。我们通过测量血清骨吸收标记物，抗酒石酸酸性磷酸酶5b（TRACP-5b）和骨形成标记物，骨特异性碱性磷酸酶（BAP）的水平，研究了接受all-HSCT的患者中BTM的实用性。 ，以及all-HSCT前1个月和6个月后的BMD。 如果在allo-HSCT之前或allo-HSCT后1个月内给予阿仑膦酸盐治疗（每周口服35 mg），则将患者分为阿仑膦酸盐组（n = 14）或对照组（n  = 16），其中患者未接受阿仑膦酸盐治疗。尽管阿仑膦酸盐组的皮质类固醇激素使用者使用频率较高（71.4 vs. 18.9％; p  <0.01），但腰椎BMD的平均百分比变化（-2.9 vs.-3.1％; p  = 0.44）和股骨颈（在6个月内-3.2 vs.-4.1％; p  = 1.00），TRACP-5b水平（-4.8 vs. 9.9％; p  = 0.45）和BAP水平（6.9 vs. 1.0％; p  = 0.85）没有差异阿仑膦酸盐组和对照组之间的差异显着。此外，同种HSCT后6个月，腰椎BMD的百分比变化与TRACP-5b水平呈负相关（p  = 0.03，r = 0.40）。我们的结果表明，阿仑膦酸盐治疗异体-HSCT患者可能有效。BTM级别对于监视BMD变化可能很有用。